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C O R O N A R Y A R T E R Y C A L C I U M ( C A C ) S C A N N I N G H A S B E E N P E R -
F O R M E D for the better part of 2 decades. Initially, many in the cardiology community viewed it
keptically because there was no evidence base, and it had appearances of a marketing/money-making
loy. Once the data began to be generated that a high Agatson score, 300 or so, was associated with
levated riskbeyond thepatient’s Framinghamrisk score, it began togaingreater acceptanceas a testwith
otential benefit for risk stratification. The absolute event rate, even inpatientswithhigher scores, remains
odest, so exactly how to use the score in an individual patient remains somewhat unclear. That being
aid, in the most recent guidelines for screening asymptomatic individuals, it received a Class IIa recom-
endation, level of evidence B, for screening those at intermediate risk and a class IIb, level of evidence B,or those at low-intermediate risk (1).In this installment of iForum in iJACC, we
resent to our readers opposing views of the
ole of CAC in primary prevention. Dr. Na-
ir and colleagues present a cogent argument
or the use of CAC in screening. They pres-
nt compelling evidence of the association of
igher scores with higher risk, and of the
AC score of 0 with extremely low risk.
hey discuss the recent studies (MESA
Multi-Ethnic Study of Atherosclerosis] and
NR [Heinz Nixdorf Recall]) that show how
requently CAC can reclassify patients. They also
iscuss relative benefits of screening CAC versus
igh-sensitivity C-reactive protein (hsCRP) in re-
ation to the JUPITER (Justification for the Use
f Statins in Primary Prevention: An Intervention
rial Evaluating Rosuvastatin) trial. They pointout that patients with low hsCRP were excluded
from JUPITER, and thus it cannot be viewed as
a screening trial involving all comers. They point
out that patients in JUPITER with a CAC of 0
would receive therapy with little benefit, given
their extremely low event rate.
Presenting the opposing view, Drs. Ridker
and Pena explain that since there is strong
evidence based on the JUPITER trial that
one can treat with statin therapy based on
hsCRP 2 and that no such evidence base exists
for CAC, that hsCRP is the appropriate bio-
marker to use for primary prevention decision
making. They present the potential downsides of
CAC including radiation (albeit quite low) and
the issue of noncardiac findings that generate ad-
ditional testing. They make a case for the need for
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112“screen and treat” intervention data for
CAC. They propose a concept for a trial
of CAC in patients with low levels of
low-density lipoprotein (LDL), high lev-
els of high-density lipoprotein cholesterol
(HDLC), and low hsCRP with ran-
domized statin therapy, with examina-
tion of the results based on high or low
CAC scores. This would indeed be an
interesting study and just the kind of
dialogue that iForum is designed to cre-
ate.
CAC Scanning for
Primary Prevention: Pros
Khurram Nasir, MD, MPH*†‡
Leslee J. Shaw, PHD§
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CLINICAL DECISION MAKING FOR
PRIMARY PREVENTION OF CARDIO-
VASCULAR DISEASE (CVD) in asymp-
tomatic individuals is traditionally
guided by an initial estimate of the
Table 1. Predictive Value of CAC Testing
Measures of association
Hazard ratios (95% CI)
Measure of discrimination
AUC
Measure of reclassiﬁcation
Net reclassiﬁcation improvement
Risk factors include age, sex, ethnic group, cigarette smokin
pressure, and use or nonuse of lipid-lowering or antihypert
AUC  area under the receiver-operating characteristic curve; Cimpact of single or clustered labora-
tory and risk factors as they relate to
the risk of a coronary event. Extensive
evidence demonstrates that current
traditional approaches lack precision
and accuracy in predicting future CVD
risk among asymptomatic individuals.
Considering the fact that CVD not
only is associated with a high morbidity
and mortality, but is also responsible for
the large share of the healthcare budget,
there is an urgent need for improved
risk assessment methods to accurately
identify not only those “at higher risk,”
but also those at “very low risk,” for ap-
propriate allocation of finite resources to
reduce the CVD burden in a cost-effec-
tive manner.
Since atherosclerosis appears to be
the main culprit for the development of
a majority of these events, screening for
subclinical atherosclerosis, such as CAC,
may aid in supplementing current global
risk assessment approaches. In order to
establish the role of CAC testing in
primary preventive settings, the evi-
dence needs to be critically assessed as
to whether the information gained is
additive to assessments made by less ex-
pensive office-based measures.
Association of elevated CAC scores with
cardiovascular risk. Over the last de-
cade, multiple studies have shown the
strong prognostic value of CAC in
predicting CVD events. However, it is
important to keep in mind study gen-
ti-Ethnic Study of Atherosclerosis (N  6,722)
CAC 0 (reference group)
CAC 1–100 3.6 (1.9–6.6)
CAC 101–300 7.7 (4.1–14.5)
CAC300 9.7 (5.2–17.9)
AUC risk factors 0.77
AUC risk factors CAC 0.82*
Total population 25%
Intermediate risk 54.4%
resence or absence of diabetes, total cholesterol level, high-d
e medication. *p 0.001 vs. risk factors.
AC  coronary artery calcium; CI  conﬁdence interval; FRS  Freralizability of these retrospective co-
horts, validity of risk factor and resul-
tant multivariable models, and risk of
test-induced bias. These concerns were
addressed with recent prospective reg-
istries such as MESA (2) and the HNR
study (3) showing 9- to 16-fold higher
hazard ratios for individuals with severe
CAC compared with those with no
CAC. To date, a plethora of available
data consistently shows that at least
two-thirds of all events are concen-
trated among one-fourth of the popu-
lation with CAC 100 (2–5), a pre-
dictive value not seen with any other
known risk factor or biomarker.
Discrimination and reclassiﬁcation with
CAC testing. Although the extent of
CAC has been shown to predict cardiac
events in asymptomatic patients with
hazard ratios up to 10-fold, decisions
about the predictive utility of new tests,
however, should be made based on a
particular test’s discrimination and re-
classification ability above and beyond
the standard traditional risk factors.
CAC scanning has been shown to re-
sult in substantial improvement in risk
discrimination, as well as significantly
high-risk reclassification in the MESA
and HNR studies (Table 1). Notably,
among intermediate-risk patients, the
use of CAC is associated with a net
reclassification improvement of 55%. In
comparison, studies comparing con-
ventional and newer biomarkers for
predicting cardiovascular events have
consistently demonstrated that adding
a number of newer biomarkers (such as
Heinz Nixdorf Recall Study (N  4,129)
CAC 0 (reference group)
CAC 1–99 1.7 (0.8–3.5)
CAC 100–399 4.0 (2.0–8.1)
CAC 400–999 5.4 (2.4–12.3)
CAC 1,000 16.1 (8.0–32.2)
AUC FRS 0.681
AUC CAC 0.741, p 0.046 vs. FRS
AUC FRS  CAC 0.749, p 0.003 vs. FRS
Total population 22.4%
Intermediate risk 65.6%
ty lipoprotein cholesterol level, systolic and diastolic bloodMul
g, p ensi
ensivamingham Risk Score.
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113hsCRP) only results in minimal im-
provement in risk discrimination and
reclassification.
Negative likelihood of absence of CAC.
Apart from the ability to identify those
“high-risk” individuals, among whom
the majority of events occur, absence of
CAC confers a very low risk for future
CVD events and mortality. In a series
of studies including a meta-analysis, we
have shown that among 29,312 indi-
viduals without evidence of CAC, only
0.56% of subjects without CAC expe-
rienced a CVD event during a mean
follow-up period of 51 months (5)
(Table 2). These findings were con-
firmed in a large retrospective study (6)
and a multiethnic prospective study (7)
demonstrating a very low risk with
CAC  0. A finding of CAC  0
confers such low risk that clinicians
may elect to focus on lifestyle therapies
without need for further cardiac testing
or medications. On the other hand,
none of the traditional risk factors and
novel serum biomarkers has sufficient
sensitivity to exclude clinically impor-
tant coronary events.
Based on the preceding evidence,
there is little doubt of the superiority of
the CAC test as far as prediction and
reclassification of CVD risk is con-
cerned. However several “criticisms”
have been raised in regard to the role of
CAC testing within the current pri-
mary CVD preventive efforts. In the
following section, we would like to
address a few of these concerns.
• CAC testing is associated with sig-
nificant radiation: The mean effec-
tive radiation dose of a CAC scan
when using appropriate protocols is
1 mSv, a dose that is comparable
to a mammogram. This radiation
burden is sizably less than the aver-
Table 2. Prognostic Value of CAC  0 Among A
Study Type, Ref. # Total Popul
Meta-analysis (4) 71,59
Retrospective study (5) 44,05
Prospective study (6) 6,80CAC  coronary artery calcium; CHD  coronary heart disease;age annual exposure from ionizing
radiation in the United States,
which is 3 mSv. If the radiation
associated with mammography for
breast cancer screening performed
annually in women older than 45
years of age is acceptable, we believe
it should be less of a concern to screen
for CAD (once in a lifetime and thus
far less cumulative radiation exposure
than yearly mammography), consider-
ing its mortality burden is 10-fold
higher than breast cancer.
• CAC testing leads to increase
downstream testing and costs:
This myth was recently debunked by
the EISNER (Early Identification
of Subclinical Atherosclerosis by
Noninvasive Imaging Research) trial,
which showed that overall rates of
downstream medical testing and
procedures, including stress tests as
well as revascularizations, did not
differ among the scan and no-scan
groups, resulting in comparable costs
during follow-up of 4 years (8)
(Table 3). Most importantly among
patients with CAC  0, there was a
37% and 25% greater reduction in
downstream procedure and medications
ptomatic Individuals
n, N CAC  0, n (%) F
29,312 (41%)
19,898 (45%)
3,414 (50%)
Table 3. Comparison of Downstream Testing an
Testing in 4-Year Follow-Up
No CAC Testing
Downstream tests
Stress test 33.9%
Cardiac CT 7.1%
Cardiac catheterization 2.9%
Coronary revascularization 1.8%
Downstream costs
Median procedure costs* $721
Median medication costs $2,937
Adapted from Rozanski et al. (8). *Includes $150 for corona
CT  computed tomography.CVD  cardiovascular disease.costs, respectively, compared with those
not undergoing any CAC testing.
• CAC testing does not change pa-
tient and physician behavior:
Emerging evidence indicates that
those with higher CAC scores are
more likely to stimulate improved
lifestyle changes and cause adher-
ence/initiation to cardioprotective
medications, which is the corner-
stone of reducing future CVD
events (8). In comparison, we do not
know of any study providing similar
data with novel biomarkers such as
hsCRP.
• CAC versus CRP: Why assess
CAC when hsCRP screening
identifies those who will benefit
with lipid-lowering pharmaco-
therapy where no such evidence
exists for CAC testing? In the
recent JUPITER trial, a 44% reduc-
tion was noted among men 50
years of age and women 60 years
of age with no prior history of CVD
with LDL levels 130 mg/dl and
hsCRP 2.0 mg/l with rosuvastatin
20 mg daily. Many critics used this
study finding to demand similar
studies with CAC testing, as well as
w-Up, Yrs Number of Events, %
4.3 154 (0.47%) CVD events
5.6 104 (0.52%) deaths
4.1 17 (0.52%) CHD events
sts Among Those Undergoing No CAC vs. CAC
623) CAC Testing (n  1,311) p Value
34.6% 0.74
7.7% 0.62
3.3% 0.71
2.3% 0.46
$904 0.56
$3,149 0.09
ery calcium (CAC) testing.sym
atio ollo
5
2
9d Co
(n 
ry art
c1
2
3
4
5
6
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 , 2 0 1 2
J A N U A R Y 2 0 1 2 : 1 1 1 – 8
Nasir et al.
CAC Scanning in Primary Prevention
114using these data to justify hsCRP
screening in asymptomatic individuals
to identify those who will benefit from
lipid-lowering pharmacotherapy.
In response, the following should be
onsidered.
. JUPITER was not a “screening trial”;
those with lower hsCRP levels were
specifically excluded. In the absence
of a “low-LDL/low-hsCRP” arm, it
is impossible to determine whether
the benefit seen with rosuvastatin
was based at all upon the presence of
elevated hsCRP.
. A post hoc analysis of JUPITER
found the benefit of lipid-lowering
management was greater in those
with hsCRP levels lower than the
median (4.2 mg/l), suggesting that
the effect of pharmacotherapy, if
not better, would be the same
among those with lower CRP (2
mg/l) who were excluded from the
trial. In that scenario, the role of
“CRP screening” is highly ques-
tionable.
. On the other hand, the St. Francis
Heart Study demonstrated that
atorvastatin 20 mg significantly
lowered events in patients with
CAC 400 (8.7% vs. 15.0%, p 
0.046 [42% reduction]), whereas a
nonsignificant 30% reduction was
noted among those with lower
CAC scores (9). This is consistent
with the hypothesis that individuals
with higher risk (as accurately iden-
tified by CAC) will confer greater
benefit, whereas lesser event reduc-
tions will be noted among those at
relatively lower risk (lower CAC
scores).
. Further evidence to the preceding hy-
pothesis was provided by our recent
study demonstrating that among par-
ticipants meeting JUPTER criteria,
CAC was absent in nearly one-half
of the individuals’ CAC scores and
during a 6-year follow-up (almost
3-fold more than the JUPITER
trial), rates of coronary events were
0.8/1,000 person-years (5). Themajority (74%) of all coronary
events occurred in only one-fourth
of participants with CAC 100
(20.2 per 1,000 person-years). Ap-
plying the effect of rosuvastatin
from the JUPITER trial to this
population, the number needed to
treat (NNT) to prevent 1 coronary
event was inappropriately high
(n  549) for CAC  0. On the
other hand, the NNT for any CAC
was 42 and as low as 24 for CAC
100. In addition, among those
with LDL 130 mg/dl, CAC 0
was associated with a 4-fold higher
risk of coronary heart disease events
and as high as 9-fold for CAC
100. In comparison, the respec-
tive HR for hsCRP 2 versus 2
mg/l was 0.90 (0.54 to 1.50). As
shown in Figure 1, clearly CAC has
been significantly superior to hsCRP
in predicting events among those
with LDL 130 mg/dl.
. One must acknowledge that it is
difficult to prevent events if they
rarely occur. We demonstrated
that nearly 50% of patients fitting
JUPITER criteria have no CAC,
and experience an extremely low
event rate of 1 per 1,000 patient-
years (1% 10-year event rate).
Figure 1. CHD Event Rates (Per 1,000 Person-Ye
Event rates are according to C-reactive protein (CR
those with low-density lipoprotein 130 mg/dl. Ad
CHD  coronary heart disease.Within this specific cohort (n 
444), no one suffered a myocardial
infarction or cardiovascular death
(hard event), and only 2 had soft cor-
onary heart disease events in 6 years of
follow-up (4).
. In our estimate, even if statins
could prevent every event in this
population, the 5-year NNT would
still be over 200 (4). Based on this
undeniably strong evidence of ex-
cellent prognosis for those with
CAC  0, would the critics still
argue that the majority of the
event reductions in JUPITER
would occur in those with CAC 0
rather than the higher-risk indi-
viduals with detectable CAC,
among whom the majority of
events occur?
Conclusions. Detection of CAC as a
measure of subclinical coronary athero-
sclerosis provides an integrated view of
the cumulative exposure to exposure
over an individual’s lifetime, explaining
its superior performance to individual
risk factors/biomarkers measured at
single time points. The unique role of
CAC testing is in its “power of zero”
(3–6). Since all nonspecific biomarkers,
including hsCRP, cannot really rule out
d coronary artery calcium (CAC) levels among
d, with permission, from Blaha et al. (4).ars)
P) an
apte
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115disease, they can only be used to raise
risk estimates, and thus are inextricably
tied to more treatment and down-
stream cost. In the current environment
of rising healthcare costs and shrinking
resources, we cannot afford to treat a
large number of individuals to prevent
few events and are obligated to priori-
tize how best to allocate our limited
resources to reduce the overall eco-
nomic healthcare cost burden. Based
on clinical equipoise, current treatment
strategies should be based to match
one’s clinical risk to limit both under-
and overtreatment by using CAC to
guide therapy intensity. Finally, we
would like to end this debate with a
question, “Would you be more reas-
sured about a patient’s prognosis if the
hsCRP was below 2 mg/l or if CAC 
0?” Based on emerging data, the choice
is clear.
CAC Scanning for
Primary Prevention: Cons
Paul M. Ridker, MD, MPH*
Jessica M. Peña, MD, MPH*
*Center for Cardiovascular Disease Pre-
vention and the Divisions of Preventive
Medicine and Cardiovascular Medicine,
Brigham and Women’s Hospital, Har-
vard Medical School, Boston, Massachu-
setts
IN PRIMARY PREVENTION, IT IS NOT
SUFFICIENT TO ORDER A SCREENING
TEST simply because it improves risk
prediction. The screening test must
also lead to a specific risk-lowering
intervention that the patient would
otherwise not receive. Since all pa-
tients should receive advice on exer-
cise, smoking cessation, and dietary
discretion, the main reason to order a
screening test for cardiovascular risk
assessment in primary prevention is to
ascertain who will benefit from statin
therapy.
What is known from randomized
trials for “screen and treat” statinstrategies based on simple blood bio-
markers such as LDL cholesterol,
HDL cholesterol, and hsCRP? And
for comparison, what is known for
“screen and treat” statin strategies
based on CAC in the setting of pri-
mary prevention?
First, if LDL cholesterol is high
(Fig. 2, Quadrant A), physicians can
reliably prescribe statin therapy to re-
duce cardiovascular risk. As demon-
strated in the randomized, double-
blind, placebo-controlled WOSCOPS
(West of Scotland Coronary Preven-
tion Study) trial (10), random alloca-
tion to pravastatin among those with
elevated LDL cholesterol reduced
rates of first coronary events by 31%
(95% confidence interval [CI]: 17
to 43).
Second, if HDL cholesterol is low
(Fig. 2, Quadrant B), physicians can
also reliably prescribe statin therapy to
reduce cardiovascular risk. This find-
ing was demonstrated clearly in the
AFCAPS/TexCAPS (Airforce Texas
Coronary Atherosclerosis Prevention
Study) trial (11) in which random al-
Figure 2. Evidence-Based “Screen and Treat” Str
AFCAPS/TexCAPS  Airforce Texas Coronary Athero
ease; HDL  high-density lipoprotein; JUPITER  Ju
vention Trial Evaluating Rosuvastatin; LDL  low-d
Coronary Prevention Study.location to lovastatin among thosewith low HDL cholesterol reduced
rates of first coronary events by 37%
(95% CI: 21 to 50).
Third, if hsCRP is high (Fig. 2,
Quadrant C), physicians can further
reliably prescribe statin therapy to re-
duce cardiovascular risk even if the
patient already has a low LDL cho-
lesterol level. This is the fundamental
finding of the JUPITER trial (12),
where rosuvastatin reduced the risk of
vascular events by 44% (95% CI: 31
to 54) among men and women with
hsCRP 2 mg/l who had levels of
LDL cholesterol 130 mg/dl.
Thus, among primary prevention
patients screened for elevated LDL
cholesterol (Quadrant A), low HDL
(Quadrant B), or elevated hsCRP
(Quadrant C), the clinical community
already has hard trial evidence that
providing statin therapy (an interven-
tion the patient otherwise would not
receive) significantly reduces cardio-
vascular event rates. As statins are
both cost effective and low risk, there
is no reason to withhold treatment
from patients where a “screen and
ies in the Primary Prevention of CVD
rosis Prevention Study; CVD  cardiovascular dis-
cation for Use of Statins in Prevention: An Inter-
ty lipoprotein; WOSCOPS  West of Scotlandateg
scle
stiﬁ
ensitreat” strategy has proven effective,
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116unless a clinical contraindication is
present. Further, for patients in
Quadrants A, B, or C of Figure 2
who already have an indication for
statin therapy, there is no current rea-
son to obtain a CAC scan, particu-
larly as knowledge of the CAC score
does not improve statin compliance
nor do statins reduce CAC. It is pos-
sible that CAC scanning might pro-
vide a mechanism to reduce the NNT
for those in Quadrants A, B, and C,
but this has never been formally
tested.
What about patients in Quadrant
D of Figure 2 who have low LDL
cholesterol, high HDL cholesterol,
and low hsCRP? This group includes
apparently healthy men and women at
low absolute cardiovascular risk, al-
most all of whom have 10-year
Framingham or Reynolds estimated
risks well below 10%.
Is there any evidence that individu-
als in Quadrant D benefit from statin
therapy? Regrettably, there is not.
Does CAC identify higher-risk in-
dividuals in this group? Perhaps, but
most studies to date have not focused
here and include instead the many
primary prevention patients in Quad-
rants A, B, and C, who already have
an indication for therapy. But even if
we knew with clarity that CAC does
identify higher risk among those with
low LDL cholesterol, high HDL
cholesterol, and low hsCRP, we still
would not know without randomized
trial evidence that this group prefer-
entially benefits from statin treatment.
In fact, as clinical trials have re-
peatedly shown, physicians cannot as-
sume efficacy for statins in any un-
studied patient group. Consider, for
example, that 4 major trials of statin
therapy—AURORA (A Study to
Evaluate the Use of Rosuvastatin in
Subjects on Regular Hemodialysis: An
Assessment of Survival and Cardiovas-cular Events), CORONA (Controlled
Rosuvastatin in Multinational Trial in
Heart Failure), 4D (Deutsche Diabetes
Dialyse Studie), and GISSI-HF
(GISSI-HF–Effects of n-3 PUFA and
Rosuvastatin on Mortality-Morbidity of
Patients With Symptomatic CHF)
(13–16)—all failed to demonstrate
benefits of treatment when compared
with placebo. Data from these trials
are particularly relevant to the imag-
ing community since each enrolled
high-risk patients with considerable
underlying atherosclerosis, and thus
represent patient groups likely to have
high CAC scores. So at least for now,
it is impossible to make an argument
that the presence of CAC guarantees
a benefit from statin therapy.
Critics of CAC note that the tech-
nique requires considerable infrastruc-
ture investment, is expensive com-
pared with simple blood biomarkers,
is associated with radiation exposure,
and leads to incidental radiographic
findings that often necessitate further
expense and repeat radiation. All of
these issues are substantive, and cre-
ative work is being done by many in-
vestigators to reduce hazards through
optimized imaging protocols and im-
proved clinical decision algorithms.
However, even if these other short-
comings were absent, we should not
endorse CAC scanning in primary
prevention without clear “screen and
treat” intervention data.
It is a paradox of prevention that
most individuals destined to suffer a
cardiovascular event have low-to-
moderate absolute risk and cholesterol
levels that do not meet current
thresholds for treatment. A further
complexity of the prevention paradox
for statins is that discordance exists
between relative risk reduction and
absolute risk reduction associated
with these drugs. U.S. and European
guidelines typically assume that as anindividual’s risk of a cardiovascular
event increases, the relative risk re-
duction derived from statin therapy
either increases or remains stable.
However, as shown in Figure 3, there
is an inverse relationship between ab-
solute risk of a major coronary event
and the relative risk reduction
achieved with statin therapy. Namely,
as the absolute risk of a major coro-
nary event decreases in the trial popu-
lation, the observed relative risk re-
duction increases.
This latter observation raises the
possibility that early use of statins
may be the most effective way to
eliminate cardiovascular disease. Slow-
ing the initial steps of atherogenesis
and early lesion progression appears to
be a major mechanism by which st-
atins ultimately reduce event rates.
However, early statin use from a bio-
logical perspective is likely to imply a
time frame for initiation well before
calcified plaques are present. As docu-
mented by many investigators, non-
calcified and partially calcified plaques
are more likely to rupture than heavily
calcified plaques, and vulnerability is
not easily detected by CAC alone.
Thus, there is considerable contro-
versy as to whether or not targeting
statin therapy to those with CAC is a
correct biological strategy. This is ex-
actly the kind of equipoise that can be
resolved in an appropriately designed
clinical trial.
Geoffrey Rose noted more than 2
decades ago that treatment of a large
number of people at small risk can
lead to greater population benefit than
an approach targeting high-risk indi-
viduals alone (17). A screening para-
digm predicated on the estimation of
an individual’s absolute risk and treat-
ing only those who reach certain risk
thresholds could overlook the poten-
tial public health impact of treating
the more numerous lower-risk indi-
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117viduals who contribute a significant
burden of disease. If, as described in
Figure 3, the relationship between ab-
solute risk and relative risk reduction
is inverse for statins, the potential
public health impact of an approach
targeting lower-risk individuals may
be even greater than Rose might have
conceived in the classic “prevention
paradox.”
What then might an appropriate
randomized trial designed to objec-
tively evaluate the potential for CAC
scanning in primary prevention look
like? First, we would start with those
Figure 3. Observed Relative Risk Reductions in P
Absolute Cardiovascular Risk
The annual risk of a major coronary event in the p
risk of the trial population. Data obtained from Cho
The solid line represents a regression ﬁt through t
Studie; ALERT  Assessment of Lescol in Renal Tra
Lowering Treatment to Prevent Heart Attack Trial—
Lowering to Alleviate New Cardiovascular Endpoint
comes Trial—Lipid-Lowering Arm; ASPEN  Atorva
Endpoints in Non-Insulin-Dependent Diabetes Melli
vastatin in Subjects on Regular Hemodialysis: An A
CARDS  Collaborative Atorvastatin Diabetes Study
GISSI-HF  GISSI-HF–Effects of n-3 PUFA and Rosuv
tomatic CHF; GISSI-P  GISSI-Prevenzione; LIPID 
Disease; LIPS  Lescol Intervention Prevention Stud
the Primary Prevention Group of Adult Japanese; P
PER  Prospective Study of Pravastatin in the Elde
Study; other abbreviations as in Figure 2.in Quadrant D of Figure 2. Individu-als with low LDL cholesterol, high
HDL cholesterol, and low hsCRP do
not have a current indication for sta-
tin therapy, and no trial being con-
ducted at this time includes such in-
dividuals. Thus, there would be no
threat of “drop in” in the placebo
group if this group were enrolled.
Second, we would randomize all
participants in a 1:1 manner between
statin and placebo, preferably using a
potent generic statin at a fixed dose.
All participants would then be fol-
lowed over an approximate 5-year pe-
riod for major incident cardiovascular
ebo-Controlled Statin Trials as a Function of
o group was used to approximate the absolute
erol Treatment Trialists Collaboration (CTT [19]).
ata points. 4D  Deutsche Diabetes Dialyse
ant; ALLHAT-LLT  Antihypertensive and Lipid-
d-Lowering Trial; ALLIANCE  Aggressive Lipid
SCOT-LLA  Anglo-Scandinavian Cardiac Out-
n Study for Prevention of Coronary Heart Disease
AURORA  A Study to Evaluate the Use of Rosu-
sment of Survival and Cardiovascular Events;
RE  Cholesterol and Recurrent Events;
tin on Mortality-Morbidity of Patients With Symp-
g-Term Intervention with Pravastatin in Ischaemic
EGA  Management of Elevated Cholesterol in
CABG  Post Coronary Artery Bypass Graft; PROS-
t Risk; SSSS  Scandinavian Simvastatin Survivalevents.Third, all participants would un-
dergo a blind baseline CAC scan
prior to randomization. The data
from this baseline scan would only
come into play after the trial was
complete and would be used in a set
of pre-specified analyses to address
formally whether any effects of statin
therapy overall are modified by the
underlying extent of calcification at
study entry. Such a simple trial design
avoids the pitfalls associated with us-
ing the baseline CAC score to dictate
subsequent therapy, a problematic
clinical trial strategy that can intro-
duce investigator bias and has the po-
tential to deliver a self-fulfilling out-
come.
There are several possible results
from such a trial, all of which would
be informative for patient care. One
possible outcome is that statin therapy
proves to be highly effective for all
participants, in which case the trial
would demonstrate little need for any
screening test at all. Such an outcome
would be important for public health
and move the field closer to a “simply
treat” strategy that would obviate the
need for LDL, HDL, hsCRP, and
CAC testing altogether.
A second potential outcome is that
statin therapy proves effective, but has
far greater efficacy among those with
high as compared with low CAC
scores. In this case, there would be
much smaller NNT values for those
with high CAC values, and CAC would
be seen as a potentially important method
to cost-effectively target statin therapy in
the general population.
A third potential outcome is that
among those with low LDL, high
HDL, and low hsCRP, statin therapy
proves to be ineffective. This is not an
impossible outcome; in the AFCAPS/
TexCAPS trial, those with low LDL
cholesterol and low hsCRP did notlac
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118apy in terms of clinical event reduc-
tion despite large reductions in LDL
cholesterol (18). Such a result would
provide a clear demonstration that
Quadrant D individuals should not be
treated with statin therapy, again a
major finding of considerable public
health importance.
A critical issue in the design of this
proposed trial is that it is unbiased for
or against imaging and thus, after a
5-year period, we would finally know
whether the correct answer to Geof- o
coronary artery calcification. J Am Coll Car-
diol Img 2009;2:675–88.
1
1
1frey Rose’s paradox is to treat all pa-
tients without screening or to treat a
few patients with screening. Such a
trial could be coordinated by the Na-
tional Heart, Lung, and Blood Insti-
tute, with costs borne by the imaging
industry, the stakeholder who stands
to benefit the most financially from a
positive outcome.
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